Pregnancy Management in Patients with Ph-Negative Myeloproliferative Neoplasms: A Literature Review and Case Report

Kristina Teimurazovna Poghosyan, A.L. Melikyan, E.A. Gilyazitdinova, I.N. Subortseva, Z.V. Tratsevskaya, E.S. Polushkina, E.E. Sudneva, E.A. Kitsenko,

DOI:

https://doi.org/10.21320/2500-2139-2026-19-2-220-228

Myeloproliferative neoplasms (MPNs) refer to a range of chronic oncohematologic clonal diseases characterized by excessive proliferation of myeloid lineage cells and/or excessive fibrosis of the bone marrow. Although MPNs are commonly diagnosed in subjects over 60 years of age, it is now increasingly detected at a young age. It is not uncommon for practitioners to encounter young pregnant patients with Ph-negative MPNs. Both pregnancy and Ph-negative MPNs are characterized by hypercoagulation increasing the risk of thrombotic complications and other adverse events associated with placental insufficiency. Pregnant MPN patients are treated with antiaggregants (aspirin) and anticoagulants (low molecular weight heparin), erythrocytapheresis or bloodletting; interferon-α is used if cytoreduction is required. This paper reports a case of management and outcomes of four pregnancies in a patient with masked polycythemia vera marked by portal vein thrombosis, portal hypertension, splenomegaly as well as esophageal and gastric fundus varices. Her first pregnancy ended in miscarriage at the early stage of gestation, her second pregnancy resulted in a premature birth, whereas her third and fourth pregnancies were successful — she delivered full-term babies. During all pregnancies, the patient received interferon-α.

  1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. doi: 10.1182/blood-2016-03-643544. DOI: https://doi.org/10.1182/blood-2016-03-643544
  2. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28. doi: 10.1182/blood.2022015850. DOI: https://doi.org/10.1182/blood.2022015850
  3. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–19. doi: 10.1038/s41375-022-01613-1. DOI: https://doi.org/10.1038/s41375-022-01613-1
  4. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management. Am J Hematol. 2020;95(12):1599–613. doi: 10.1002/ajh.26008. DOI: https://doi.org/10.1002/ajh.26008
  5. Robinson SE, Harrison CN. How we manage Philadelphia‐negative myeloproliferative neoplasms in pregnancy. Br J Haematol. 2020;189(4):625–34. doi: 10.1111/bjh.16453. DOI: https://doi.org/10.1111/bjh.16453
  6. Hultcrantz M, Ravn Landtblom A, Andréasson B, et al. Incidence of myeloproliferative neoplasms — trends by subgroup and age in a population‐based study in Sweden. J Intern Med. 2020;287(4):448–54. doi: 10.1111/joim.13019. DOI: https://doi.org/10.1111/joim.13019
  7. Roaldsnes C, Holst R, Frederiksen H, Ghanima W. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. Eur J Haematol. 2017;98(1):85–93. doi: 10.1111/ejh.12788. DOI: https://doi.org/10.1111/ejh.12788
  8. Szuber N, Vallapureddy RR, Penna D, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018;93(12):1474–84. doi: 10.1002/ajh.25270. DOI: https://doi.org/10.1002/ajh.25270
  9. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667–79. doi: 10.1182/blood-2016-10-695940. DOI: https://doi.org/10.1182/blood-2016-10-695940
  10. Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320(7251):1708–12. doi: 10.1136/bmj.320.7251.1708. DOI: https://doi.org/10.1136/bmj.320.7251.1708
  11. Bates SM, Ginsberg JS. Thrombosis in pregnancy: Curr Opin Hematol. 1997;4(5):335–43. doi: 10.1097/00062752-199704050-00007. DOI: https://doi.org/10.1097/00062752-199704050-00007
  12. Nelson SM, Greer IA. Thrombophilia and the Risk for Venous Thromboembolism during Pregnancy, Delivery, and Puerperium. Obstet Gynecol Clin North Am. 2006;33(3):413–27. doi: 10.1016/j.ogc.2006.05.009. DOI: https://doi.org/10.1016/j.ogc.2006.05.009
  13. How J, Leiva O, Bogue T, et al. Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res. 2020;98:106459. doi: 10.1016/j.leukres.2020.106459. DOI: https://doi.org/10.1016/j.leukres.2020.106459
  14. Gangat N, Tefferi A. Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. Am J Hematol. 2021;96(3):354–66. doi: 10.1002/ajh.26067. DOI: https://doi.org/10.1002/ajh.26067
  15. Randi ML, Bertozzi I, Rumi E, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol. 2014;89(3):306–9. doi: 10.1002/ajh.23635. DOI: https://doi.org/10.1002/ajh.23635
  16. Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016;175(1):31–6. doi: 10.1111/bjh.14289. DOI: https://doi.org/10.1111/bjh.14289
  17. Landtblom AR, Andersson TML, Johansson ALV, et al. Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms—a nationwide population-based study of 342 pregnancies in Sweden. Leukemia. 2022;36(10):2461–7. doi: 10.1038/s41375-022-01688-w. DOI: https://doi.org/10.1038/s41375-022-01688-w
  18. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110(2):485–9. doi: 10.1182/blood-2007-01-071068. DOI: https://doi.org/10.1182/blood-2007-01-071068
  19. Melillo L, Tieghi A, Candoni A, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. Am J Hematol. 2009;84(10):636–40. doi: 10.1002/ajh.21504. DOI: https://doi.org/10.1002/ajh.21504
  20. Maze D, Kazi S, Gupta V, et al. Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019;2(10):e1912666. doi: 10.1001/jamanetworkopen.2019.12666. DOI: https://doi.org/10.1001/jamanetworkopen.2019.12666
  21. Sokołowska B, Sobas M. Pregnancy outcomes in patients with Philadelphia negative myeloproliferative neoplasms — PALG (Polish Adult Leukemia Group) a recent, extended retrospective analysis [abstract]. Abstract EP1121 presented at: December 6, 2020; EHA Library.
  22. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol. 2009;82(5):350–3. doi: 10.1111/j.1600-0609.2009.01214.x. DOI: https://doi.org/10.1111/j.1600-0609.2009.01214.x
  23. Меликян А.Л., Суборцева И.Н., Ковригина А.М. и др. Национальные клинические рекомендации по диагностике и лечению Ph-негативных миелопролиферативных заболеваний (истинной полицитемии, эссенциальной тромбоцитемии, первичного миелофиброза) (редакция 2024 г.). Клиническая онкогематология. 2024;17(3):291–334. doi: 10.21320/2500-2139-2024-17-3-291-334. [Melikyan A.L., Subortseva I.N., Kovrigina A.M., et al. National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2024). Clinical oncohematology. 2024;17(3):291–334. doi: 10.21320/2500-2139-2024-17-3-291-334. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2024-17-3-291-334
  24. Griesshammer M, Sadjadian P, Wille K. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy. Expert Rev Hematol. 2018;11(9):697–706. doi: 10.1080/17474086.2018.1506325. DOI: https://doi.org/10.1080/17474086.2018.1506325
  25. Bauersachs R, Dudenhausen J, Faridi A, et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost. 2007;98(12):1237–45. doi: 10.1160/TH07-05-0329. DOI: https://doi.org/10.1160/TH07-05-0329
  26. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70. doi: 10.1200/JCO.2010.31.8436. DOI: https://doi.org/10.1200/JCO.2010.31.8436
  27. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myeloproliferative Neoplasms Version 1.2025. Available from: https://www.nccn.org/guidelines (accessed 03.12.2025).
  28. Lapoirie J, Contis A, Guy A, et al. Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms. J Matern Fetal Neonatal Med. 2020;33(1):49–56. doi: 10.1080/14767058.2018.1484097. DOI: https://doi.org/10.1080/14767058.2018.1484097
  29. Nørgård B, Puhó E, Czeizel AE, et al. Aspirin use during early pregnancy and the risk of congenital abnormalities: A population-based case-control study. Am J Obstet Gynecol. 2005;192(3):922–3. doi: 10.1016/j.ajog.2004.10.598. DOI: https://doi.org/10.1016/j.ajog.2004.10.598
  30. Gangat N, Singh A, Ilyas R, et al. Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies. Am J Hematol. 2024;99(10):1862–9. doi: 10.1002/ajh.27416. DOI: https://doi.org/10.1002/ajh.27416
  31. Wille K, Brouka M, Bernhardt J, et al. Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET. HemaSphere. 2023;7(5):e882. doi: 10.1097/HS9.0000000000000882. DOI: https://doi.org/10.1097/HS9.0000000000000882
  32. How J, Hobbs G. Pregnancy: MPN management before, during, and after pregnancy. Hematology. 2024;2024(1):541–6. doi: 10.1182/hematology.2024000578. DOI: https://doi.org/10.1182/hematology.2024000578
  33. Schrickel L, Heidel FH, Sadjadian P, et al. Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. J Cancer Res Clin Oncol. 2021;147(5):1481–91. doi: 10.1007/s00432-020-03430-4. DOI: https://doi.org/10.1007/s00432-020-03430-4
  34. Vachhani P, Mascarenhas J, Bose P, et al. Interferons in the treatment of myeloproliferative neoplasms. Ther Adv Hematol. 2024;15:20406207241229588. doi: 10.1177/20406207241229588. DOI: https://doi.org/10.1177/20406207241229588
  35. Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012;33(3):265–8. doi: 10.1016/j.reprotox.2011.11.003. DOI: https://doi.org/10.1016/j.reprotox.2011.11.003

Keywords:

myeloproliferative neoplasm, essential thrombocythemia, polycythemia vera, pregnancy, pregnancy complications, interferon-α

License

Copyright (c) 2026 Clinical Oncohematology. Basic Research and Clinical Practice

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Kristina Teimurazovna Poghosyan,  , National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167, e-mail: poghosyan.kristina@yahoo.com
2026-2

Downloads

Published

01.04.2026

Issue

Vol. 19 No. 2 (2026)
PREGNANCY AND ONCOHEMATOLOGY

How to Cite

Poghosyan K.T., Melikyan A.L., Gilyazitdinova E.A., et al. Pregnancy Management in Patients with Ph-Negative Myeloproliferative Neoplasms: A Literature Review and Case Report. Clinical Oncohematology. Basic Research and Clinical Practice. 2026;19(2):220–228. doi:10.21320/2500-2139-2026-19-2-220-228.

Most read articles by the same author(s)

1 2 > >>